David Duncan

Skilled Doctor with extensive experience in patient care, diagnosis and providing quality medical services. Adept at managing medical teams and resolving complex medical cases with utmost precision. Possesses outstanding organizational and communication skills.

• ACMA Leadership Meeting 2014, Orlando, Florida, 01/01/2014, Observation Management and the Two Midnight Rule in a Modern Hospital, Physician Advisor Services: Building Your Own vs. Outside Consultants (The Scenario Analysis for and against)
• Virginia and Georgia Chapter ACMA 2010-11, 01/01/2010, The Supreme Court and The Affordable Care Act
• Virginia ACMA Chapter 2015, 01/01/2015, Building and Implementing Physician Advisor Services to Meet the Needs of the Hospital and the Medical Staff
• Visiting Professor Lectures at George Mason University/Georgetown University, George Squared Program and Post-Baccalaureate Pre-Medical Program, 01/01/2011, The Affordable Care Act and The Supreme Court: Impact on Providers
• Lecturer Medical Grand Rounds, Inova Fairfax Medical Campus, 01/01/2008, Health Care Reform (various topics regarding healthcare policy, Supreme Court decisions, Medicare and Insurance Exchanges). All lectures are available upon request

• Chief Medical Resident, Georgetown University Hospital/Inova Fairfax Hospital, 01/01/1995, 12/31/1996
• Medicine Resident, Georgetown University Hospital, 01/01/1993, 12/31/1995
• Medicine Intern, Georgetown University Hospital, 01/01/1992, 12/31/1993

• Associate Residency Program Director, Georgetown University Hospital, Internal Medicine Residency, 01/01/1998, 12/31/2004
• Assistant Professor of Medicine, Georgetown University School of Medicine, 01/01/1996, present
• Clinical Instructor of Medicine, Georgetown University School of Medicine, 01/01/1995, 12/31/1996

• Anticoagulation Safety Committee, Inova Health System, 01/01/2006, present, Develops and implements anticoagulation safety protocols, order sets and metrics to manage hospital anticoagulation for patients. The committee also develops anticoagulation reversal protocols for use systemwide. This committee works in close collaboration with the Department of Pharmacy under the Pharmacy and Therapeutics Committee.
• Peer Review Committee, Internal Medicine, 01/01/2000, 12/31/2010
• Peer Review Committee, Peripheral Vascular Disease, 01/01/2006, 12/31/2010
• Case Management and Utilization Review Committee, 01/01/2006, present
• Medical Quality Improvement Committee, 01/01/2004, 12/31/2012
• Patient Safety Committee, 01/01/2004, 12/31/2007
• Internal Review Board, 01/01/1997, 12/31/1998
• Internal Medicine Board Review Course Director and Lecturer, 01/01/1996, 01/01/1996

• American College of Physicians
• American Case Management Association (ACMA)

• IAMS Award 2010, Inova Health System 2010
• Georgetown University Hospital, Clinical Faculty Award 2001 for Outstanding Education of Medical Residents
• Regents Scholarship, Medical College of Georgia 1988-1990
• Certificate of Merit Scholarship, College of Charleston 1984-1988

• Tirilazad Mesylate in Acute Ischemic Stroke: A US/Canadian 1996 - 1997 Randomized Vehicle Controlled Efficacy Trial, Upjohn, 01/01/1996, 12/31/1997
• Citicoline 500 mg in Ischemic Stroke: A Placebo Controlled 1996 Study to Determine Effects, Interneuron Pharmaceuticals, 01/01/1996, 12/31/1996
• Phase 2/3 Multicenter, Double-Blind Randomized, Placebo 1996-1997 Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of IV Aptiganel HCL vs. Placebo in Patients with an Acute Ischemic Stroke, Boehringer Ingelheim Pharmaceuticals, Inc., 01/01/1996, 12/31/1997
• Prospective, Double Blind, Placebo-Controlled, Randomized 1996-1997 Multicenter North American Study of the Safety and Efficacy of Murine Monoclonal Antibody to Tumor Necrosis Factor (TNF - MAB) for the Treatment of Patients with Septic Shock, Bayer, Inc., 01/01/1996, 12/31/1997
• Antithrombin III in Patients with Severe Sepsis - A Multinational 1996-1997 Double Blind, Randomized, Placebo Controlled Phase III Study, Centeon Pharma GMBH, 01/01/1996, 12/31/1997

• Advances in Treatment of Chronic Hepatitis C: Pegylated Interferons, Cleveland Clinic Journal of Medicine, Vol. 69, No. 2, 02/01/2002
• Determination of HFE Mutations in the Paraffin-Embedded Liver Biopsy Blocks of Patients with Hepatocellular Carcinoma, Hepatology, Vol. 34, No. 4, Pt. 2 of 2, 10/01/2001
• Mortality Associated with Hepatitis C Infection, Evidence-Based Gastroenterology and Hepatology, Vol. 2, No. 3, 08/01/2001